ANI Pharmaceuticals (NASDAQ:ANIP) Issues Earnings Results

ANI Pharmaceuticals (NASDAQ:ANIP) posted its earnings results on Friday. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25, Briefing.com reports. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. During the same period last year, the firm posted $1.05 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 12.5% compared to the same quarter last year. ANI Pharmaceuticals updated its FY 2024 guidance to 4.900-5.050 EPS and its FY24 guidance to $4.90-5.05 EPS.

ANI Pharmaceuticals Trading Up 0.5 %

Shares of NASDAQ:ANIP traded up $0.30 on Monday, hitting $61.74. 324,743 shares of the company’s stock were exchanged, compared to its average volume of 216,177. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -112.25 and a beta of 0.71. The business’s 50 day simple moving average is $58.61 and its two-hundred day simple moving average is $61.47. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ANIP shares. Raymond James raised their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday. Truist Financial raised their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Piper Sandler began coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Finally, StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.